


FORM PTO-1449/A and B (modified PTO/SB/08)  Sheet 1 of 2		APPLICATION NO.: 10/529,655	ATTY. DOCKET NO.: L0461.70156US00
		FILING DATE: November 28, 2006	CONFIRMATION NO.: 5836
		APPLICANT: Scanlan et al.	
		GROUP ART UNIT: 1642	EXAMINER: Sean E. Aeder

#### U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		6,783,961		Edwards et al.	08-31-2004
		6,835,556		Attersand et al.	12-28-2004

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			


#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Sequence Comparison cited in Application Serial No. 10/260,708 by Examiner Aeder.	
		GenBank Submission; NIH/NCBI; Accession No. AW593050.	
		GenBank Submission; NIH/NCBI; Accession No. AX463882 (PAT 07/16/2002).	
		UniGene Submission; NIH/NCBI; Accession No. HS.375082.	
		UniGene Submission; NIH/NCBI; Accession No. HS.128580.	
		AYYOUB et al., Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol. 2002 Feb 15;168(4):1717-22.	
		GUILLAUMEUX et al., Expression of HLA class I genes in meiotic and post-meiotic human spermatogenic cells. Biol Reprod. 1996 Jul;55(1):99-110.	
		LE NAOUR et al., Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res. 2001 Nov;7(11):3328-35.	
		LEE et al., Immunomic analysis of human sarcoma. Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2651-6. Epub 2003 Feb 24.	
		MARTELANGE et al., Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res. 2000 Jul 15;60(14):3848-55.	
		NAKA et al., Expression of SSX genes in human osteosarcomas. Int J Cancer. 2002 Apr 1;98(4):640-2.	
		PREUSS et al., Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev. 2002 Oct;188:43-50. Review.	
		ROSENBERG et al., Progress in human tumour immunology and immunotherapy. Nature. 2001 May 17;411(6835):380-4. Review.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 10/529,655	ATTY. DOCKET NO.: L0461.70156US00	
		FILING DATE: November 28, 2006	CONFIRMATION NO.: 5836	
		APPLICANT: Scanlan et al.		
		GROUP ART UNIT: 1642	EXAMINER: Sean E. Aeder	
Sheet	of	2		



	SCANLAN et al., Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002 Oct;188:22-32. Review.	
	SCANLAN et al., Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun. 2001 Mar 30;1:4.	
	VAN DER BRUGGEN et al., Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev. 2002 Oct;188:51-64. Review.	
	YANG et al., CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7492-7.	

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.